NURS 6521 FINAL EXAM V3 WINTER
QUARTER 2026 | WALDEN UNIVERSITY
ADVANCED PHARMACOLOGY | VERIFIED
PRACTICE QUESTIONS & ANSWERS
NURS 6521 FINAL EXAM V3 WINTER QUARTER 2026 | WALDEN UNIVERSITY
ADVANCED PHARMACOLOGY | VERIFIED PRACTICE QUESTIONS & ANSWERS
DOCUMENT OVERVIEW
• This comprehensive study guide contains verified practice questions designed to
mirror the NURS 6521 Advanced Pharmacology final exam format, with rigorous
coverage of pharmacokinetics, drug interactions, clinical applications, and patient-
specific considerations across all major drug classes.
• Study this material by reviewing each question carefully, attempting answers
before checking the rationale, and focusing on questions where you miss the
reasoning—this active recall method combined with the detailed rationales will
strengthen your pharmacological knowledge and clinical decision-making skills.
SECTION 1: PHARMACOKINETICS & DRUG INTERACTIONS (Questions 1-25)
1. A 68-year-old male with chronic kidney disease is prescribed gentamicin for
a gram-negative infection. Which pharmacokinetic parameter is most
significantly affected in this patient?
A) Absorption from the GI tract
B) Hepatic metabolism rate
C) Renal clearance
D) Protein binding capacity
E) Volume of distribution
C) Renal clearance
,Rationale: Gentamicin is an aminoglycoside antibiotic that is eliminated primarily
through glomerular filtration with minimal metabolism. In chronic kidney disease,
renal clearance is substantially reduced, leading to drug accumulation and
increased risk of nephrotoxicity and ototoxicity. While volume of distribution and
protein binding may be altered in kidney disease, the primary pharmacokinetic
concern with gentamicin is decreased renal clearance, requiring dose adjustments
based on creatinine clearance and therapeutic drug monitoring.
2. A patient taking warfarin begins therapy with phenytoin for seizure
control. Which mechanism describes the interaction occurring between these
drugs?
A) Phenytoin decreases warfarin absorption through chelation
B) Phenytoin inhibits CYP2C9, increasing warfarin levels
C) Phenytoin induces CYP2C9, increasing warfarin metabolism
D) Warfarin competitively displaces phenytoin from protein binding
E) Both drugs undergo hepatic conjugation, causing competition
C) Phenytoin induces CYP2C9, increasing warfarin metabolism
Rationale: Phenytoin is a potent inducer of cytochrome P450 enzymes, including
CYP2C9, which metabolizes warfarin. This induction increases warfarin metabolism,
reducing its anticoagulant effect and INR levels. The patient would require
increased warfarin dosing to maintain therapeutic anticoagulation. When phenytoin
is discontinued, warfarin metabolism slows, potentially causing excessive
anticoagulation if the warfarin dose is not reduced accordingly. This is a clinically
significant interaction requiring close INR monitoring.
3. An 82-year-old woman with multiple comorbidities requires polypharmacy.
She is most at risk for which type of drug interaction?
A) Pharmacodynamic interaction only
,B) Pharmacokinetic interaction only
C) Additive or synergistic pharmacodynamic interactions
D) Decreased drug bioavailability uniformly
E) Increased absorption of all medications
C) Additive or synergistic pharmacodynamic interactions
Rationale: Elderly patients on multiple medications are at highest risk for
pharmacodynamic interactions where drugs with similar effects produce additive or
synergistic responses. For example, combining multiple CNS depressants (opioids,
benzodiazepines, anticholinergics) or multiple antihypertensive agents can cause
excessive sedation or hypotension. While pharmacokinetic interactions also occur
in polypharmacy, the elderly are especially vulnerable to additive
pharmacodynamic effects due to altered sensitivity to drugs and reduced
physiological reserve, making dose adjustment and careful drug selection critical.
4. A patient with cirrhosis has significantly reduced hepatic metabolism.
Which drug would require the MOST substantial dose reduction?
A) Gentamicin (renal elimination)
B) Lisinopril (minimal metabolism)
C) Propranolol (hepatic metabolism >90%)
D) Furosemide (renal elimination)
E) Digoxin (minimal metabolism)
C) Propranolol (hepatic metabolism >90%)
Rationale: Propranolol is a beta-blocker that undergoes extensive first-pass
hepatic metabolism, with over 90% of the drug being metabolized by the liver. In
cirrhosis with portosystemic shunting and hepatic dysfunction, metabolism is
severely impaired, leading to significantly increased bioavailability and prolonged
half-life. This requires substantial dose reduction (often 50% or more) to prevent
toxicity. In contrast, gentamicin, furosemide, and lisinopril rely primarily on renal
, elimination, and digoxin undergoes minimal metabolism, making them more
dependent on renal function than hepatic function.
5. A 55-year-old female begins taking St. John's Wort for depression while
continuing oral contraceptives. What is the expected pharmacokinetic
consequence?
A) Increased estrogen levels and risk of thromboembolism
B) Decreased estrogen levels and contraceptive failure
C) Enhanced hepatic conjugation of both drugs
D) Impaired absorption of St. John's Wort
E) Decreased metabolism of oral contraceptives
B) Decreased estrogen levels and contraceptive failure
Rationale: St. John's Wort is a potent inducer of cytochrome P450 enzymes
(CYP3A4, CYP2C9) and UDP-glucuronosyltransferase. This induction increases the
metabolism of ethinyl estradiol and progestins in oral contraceptives, reducing
their serum concentrations below therapeutic levels. This can result in
breakthrough bleeding and unintended pregnancy. This is a clinically significant
interaction that requires patient education about alternative contraceptive
methods or use of backup contraception. The inducing effects can persist for weeks
after St. John's Wort is discontinued, requiring continued contraceptive precautions.
6. Which factor has the LEAST influence on drug clearance in a healthy adult?
A) Liver blood flow
B) Renal tubular secretion
C) Patient's hair color
D) Glomerular filtration rate
E) Hepatic enzyme activity
QUARTER 2026 | WALDEN UNIVERSITY
ADVANCED PHARMACOLOGY | VERIFIED
PRACTICE QUESTIONS & ANSWERS
NURS 6521 FINAL EXAM V3 WINTER QUARTER 2026 | WALDEN UNIVERSITY
ADVANCED PHARMACOLOGY | VERIFIED PRACTICE QUESTIONS & ANSWERS
DOCUMENT OVERVIEW
• This comprehensive study guide contains verified practice questions designed to
mirror the NURS 6521 Advanced Pharmacology final exam format, with rigorous
coverage of pharmacokinetics, drug interactions, clinical applications, and patient-
specific considerations across all major drug classes.
• Study this material by reviewing each question carefully, attempting answers
before checking the rationale, and focusing on questions where you miss the
reasoning—this active recall method combined with the detailed rationales will
strengthen your pharmacological knowledge and clinical decision-making skills.
SECTION 1: PHARMACOKINETICS & DRUG INTERACTIONS (Questions 1-25)
1. A 68-year-old male with chronic kidney disease is prescribed gentamicin for
a gram-negative infection. Which pharmacokinetic parameter is most
significantly affected in this patient?
A) Absorption from the GI tract
B) Hepatic metabolism rate
C) Renal clearance
D) Protein binding capacity
E) Volume of distribution
C) Renal clearance
,Rationale: Gentamicin is an aminoglycoside antibiotic that is eliminated primarily
through glomerular filtration with minimal metabolism. In chronic kidney disease,
renal clearance is substantially reduced, leading to drug accumulation and
increased risk of nephrotoxicity and ototoxicity. While volume of distribution and
protein binding may be altered in kidney disease, the primary pharmacokinetic
concern with gentamicin is decreased renal clearance, requiring dose adjustments
based on creatinine clearance and therapeutic drug monitoring.
2. A patient taking warfarin begins therapy with phenytoin for seizure
control. Which mechanism describes the interaction occurring between these
drugs?
A) Phenytoin decreases warfarin absorption through chelation
B) Phenytoin inhibits CYP2C9, increasing warfarin levels
C) Phenytoin induces CYP2C9, increasing warfarin metabolism
D) Warfarin competitively displaces phenytoin from protein binding
E) Both drugs undergo hepatic conjugation, causing competition
C) Phenytoin induces CYP2C9, increasing warfarin metabolism
Rationale: Phenytoin is a potent inducer of cytochrome P450 enzymes, including
CYP2C9, which metabolizes warfarin. This induction increases warfarin metabolism,
reducing its anticoagulant effect and INR levels. The patient would require
increased warfarin dosing to maintain therapeutic anticoagulation. When phenytoin
is discontinued, warfarin metabolism slows, potentially causing excessive
anticoagulation if the warfarin dose is not reduced accordingly. This is a clinically
significant interaction requiring close INR monitoring.
3. An 82-year-old woman with multiple comorbidities requires polypharmacy.
She is most at risk for which type of drug interaction?
A) Pharmacodynamic interaction only
,B) Pharmacokinetic interaction only
C) Additive or synergistic pharmacodynamic interactions
D) Decreased drug bioavailability uniformly
E) Increased absorption of all medications
C) Additive or synergistic pharmacodynamic interactions
Rationale: Elderly patients on multiple medications are at highest risk for
pharmacodynamic interactions where drugs with similar effects produce additive or
synergistic responses. For example, combining multiple CNS depressants (opioids,
benzodiazepines, anticholinergics) or multiple antihypertensive agents can cause
excessive sedation or hypotension. While pharmacokinetic interactions also occur
in polypharmacy, the elderly are especially vulnerable to additive
pharmacodynamic effects due to altered sensitivity to drugs and reduced
physiological reserve, making dose adjustment and careful drug selection critical.
4. A patient with cirrhosis has significantly reduced hepatic metabolism.
Which drug would require the MOST substantial dose reduction?
A) Gentamicin (renal elimination)
B) Lisinopril (minimal metabolism)
C) Propranolol (hepatic metabolism >90%)
D) Furosemide (renal elimination)
E) Digoxin (minimal metabolism)
C) Propranolol (hepatic metabolism >90%)
Rationale: Propranolol is a beta-blocker that undergoes extensive first-pass
hepatic metabolism, with over 90% of the drug being metabolized by the liver. In
cirrhosis with portosystemic shunting and hepatic dysfunction, metabolism is
severely impaired, leading to significantly increased bioavailability and prolonged
half-life. This requires substantial dose reduction (often 50% or more) to prevent
toxicity. In contrast, gentamicin, furosemide, and lisinopril rely primarily on renal
, elimination, and digoxin undergoes minimal metabolism, making them more
dependent on renal function than hepatic function.
5. A 55-year-old female begins taking St. John's Wort for depression while
continuing oral contraceptives. What is the expected pharmacokinetic
consequence?
A) Increased estrogen levels and risk of thromboembolism
B) Decreased estrogen levels and contraceptive failure
C) Enhanced hepatic conjugation of both drugs
D) Impaired absorption of St. John's Wort
E) Decreased metabolism of oral contraceptives
B) Decreased estrogen levels and contraceptive failure
Rationale: St. John's Wort is a potent inducer of cytochrome P450 enzymes
(CYP3A4, CYP2C9) and UDP-glucuronosyltransferase. This induction increases the
metabolism of ethinyl estradiol and progestins in oral contraceptives, reducing
their serum concentrations below therapeutic levels. This can result in
breakthrough bleeding and unintended pregnancy. This is a clinically significant
interaction that requires patient education about alternative contraceptive
methods or use of backup contraception. The inducing effects can persist for weeks
after St. John's Wort is discontinued, requiring continued contraceptive precautions.
6. Which factor has the LEAST influence on drug clearance in a healthy adult?
A) Liver blood flow
B) Renal tubular secretion
C) Patient's hair color
D) Glomerular filtration rate
E) Hepatic enzyme activity
